2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. SGLT

SGLT

Sodium-dependent glucose cotransporters

SGLT

Related Products

PDF 0.51 MB

SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption. The two most well-known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. The two transporters are of primary importance for glucose homeostasis by absorbing glucose from the diet in the small intestine (via SGLT1) and by reabsorbing the filtered glucose in the tubular system of the kidney (primarily SGLT2; to smaller extent via SGLT1); the latter process returns glucose into the blood stream and prevents urinary glucose loss. SGLT1 and SGLT2 have been proposed as a novel therapeutic strategy for diabetes and cardiomyopathy.

SGLT Isoform Specific Products:

SGLT Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-109018
    Velagliflozin
    		Inhibitor 99.92%
    Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
    Velagliflozin
  • HY-15461A
    Ertugliflozin L-pyroglutamic acid
    		Inhibitor 99.84%
    Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
    Ertugliflozin L-pyroglutamic acid
  • HY-10450S
    Dapagliflozin-d5
    		Inhibitor 98.01%
    Dapagliflozin-d5 is a deuterium labeled Dapagliflozin. Dapagliflozin is a competitive SGLT2 inhibitor[1].
    Dapagliflozin-d<sub>5</sub>
  • HY-14945
    Remogliflozin etabonate
    		Inhibitor 99.81%
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.
    Remogliflozin etabonate
  • HY-15409S
    Empagliflozin-d4
    		Inhibitor
    Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].
    Empagliflozin-d<sub>4</sub>
  • HY-116223
    Tianagliflozin
    		Inhibitor 99.96%
    Tianagliflozin is a sodium/glucose cotransporter 2 (SGLT-2) inhibitor with potential for investigation in type 2 diabetes.
    Tianagliflozin
  • HY-109144
    Enavogliflozin
    		Inhibitor 98.01%
    Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
    Enavogliflozin
  • HY-13414
    Remogliflozin
    		Inhibitor
    Remogliflozin is a potent and selective inhibitor of SGLT2 (sodium-glucose cotransporter 2) with Kis of 12.4 and 26 nM for human and rat SGLT2, respectively. Remogliflozin is the active form of Remogliflozin etabonate(HY-14945).
    Remogliflozin
  • HY-14894A
    Ipragliflozin L-Proline
    		Inhibitor 99.94%
    Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
    Ipragliflozin L-Proline
  • HY-101782
    HSK0935
    		Inhibitor
    HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
    HSK0935
  • HY-10449
    Luseogliflozin
    		Inhibitor 99.20%
    Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.
    Luseogliflozin
  • HY-12611
    Sergliflozin etabonate
    		Inhibitor 99.64%
    Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.
    Sergliflozin etabonate
  • HY-10451S
    Canagliflozin-d4
    		Inhibitor 99.04%
    Canagliflozin-d4 is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor[1].
    Canagliflozin-d<sub>4</sub>
  • HY-128723
    Dapagliflozin impurity
    		99.63%
    Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor.
    Dapagliflozin impurity
  • HY-138944
    SGLT1/2-IN-1
    		Inhibitor
    SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .
    SGLT1/2-IN-1
  • HY-101122
    LX2761
    		Inhibitor
    LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 in vitro with IC50s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract.
    LX2761
  • HY-123011
    Henagliflozin
    		Inhibitor
    Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research.
    Henagliflozin
  • HY-153113
    Rongliflozin
    		Inhibitor
    Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM).
    Rongliflozin
  • HY-112807
    SGLT inhibitor-1
    		Inhibitor
    SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively.
    SGLT inhibitor-1
  • HY-10449A
    Luseogliflozin hydrate
    		Inhibitor 99.20%
    Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM).
    Luseogliflozin hydrate
SGLT Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.